Incb 00928-105 A Phase 1/2, Open-Label, Multicenter Study Of Incb000928 Administered As A Monotherapy In Participants With Anemia Due To Myelodysplastic Syndromes Or Multiple Myeloma
Posted Date: Jul 13, 2021
- Investigator: Emily Curran
- Specialties: Cancer, Oncology
- Type of Study: Drug
The purpose of this study is to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia. Efficacy will be determined by measuring the number of treatment-related adverse events.
Criteria:
Participants Must Agree To Avoid Pregnancy Or Fathering Children, Participants Must Be Transfusion-Dependent Or Present With Symptomatic Anemia, Must Be Ineligible To Receive Or Have Not Responded To Available Therapies For Anemia Such As Esas Or Lenalido
Keywords:
Myeloma
For More Information:
Uc Cancer Center
5135847698
cancer@uchealth.com